Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection
<p>Abstract</p> <p>Background</p> <p>West Nile Virus (WNV) is endemic in Israel and a significant level of antibodies is present in the population due to natural exposure. Anecdotal cases suggested that the presence of anti-WNV antibodies in intravenous immunoglobulin (...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-02-01
|
| Series: | BMC Infectious Diseases |
| Online Access: | http://www.biomedcentral.com/1471-2334/9/18 |
| _version_ | 1818273770999119872 |
|---|---|
| author | Gottreich Ahuva Laub Orgad Nur Israel Khinich Yevgeny Samina Itzchak Gershoni-Yahalom Orly Ben-Nathan David Simanov Michael Porgador Angel Rager-Zisman Bracha Orr Nadav |
| author_facet | Gottreich Ahuva Laub Orgad Nur Israel Khinich Yevgeny Samina Itzchak Gershoni-Yahalom Orly Ben-Nathan David Simanov Michael Porgador Angel Rager-Zisman Bracha Orr Nadav |
| author_sort | Gottreich Ahuva |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>West Nile Virus (WNV) is endemic in Israel and a significant level of antibodies is present in the population due to natural exposure. Anecdotal cases suggested that the presence of anti-WNV antibodies in intravenous immunoglobulin (IVIG) from Israeli donors (IVIG-IL) assisted the recovery of patients with severe WNV infection.</p> <p>Methods</p> <p>To enhance the therapeutic efficacy of IVIG-IL against WNV infection, OMRIX Biopharmaceuticals, Israel, have developed a strategy for selection of plasma units from a 10% fraction of Israeli blood donors with anti-WNV antibodies. Positive units were processed into pharmaceutical grade WNV IVIG (WNIG). Following inoculation with WNV, mice received i.p. injections of different doses (0.01–8 mg/mouse) of IVIG-IL or WNIG, according to the specific experimental protocol.</p> <p>Results</p> <p>WNIG was about 10 times more potent (per gr of IgG) than was regular IVIG-IL when tested by ELISA and neutralization assays. In a mouse lethal WNV infection model, prophylactic treatment with WNIG was at least 5–10-fold more potent as compared to treatment with IVIG-IL. Treatment with WNIG during active encephalitis, three or four days following WNV infection, had a significant protective effect. WNIG was also very effective in protecting immunosuppressed mice. Indeed, treatment of dexamethasone-immunosuppressed mice with 0.2 or 1.0 mg WNIG 4 h after virus infection, led to 100% survival.</p> <p>Conclusion</p> <p>IVIG produced from selected plasma donated in WNV endemic regions can be used to produce WNV IVIG with superior activity for therapeutic and prophylactic measures.</p> |
| first_indexed | 2024-12-12T22:03:15Z |
| format | Article |
| id | doaj.art-ba4f241482da4bbaac3ab05182e11c41 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-12T22:03:15Z |
| publishDate | 2009-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-ba4f241482da4bbaac3ab05182e11c412022-12-22T00:10:28ZengBMCBMC Infectious Diseases1471-23342009-02-01911810.1186/1471-2334-9-18Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infectionGottreich AhuvaLaub OrgadNur IsraelKhinich YevgenySamina ItzchakGershoni-Yahalom OrlyBen-Nathan DavidSimanov MichaelPorgador AngelRager-Zisman BrachaOrr Nadav<p>Abstract</p> <p>Background</p> <p>West Nile Virus (WNV) is endemic in Israel and a significant level of antibodies is present in the population due to natural exposure. Anecdotal cases suggested that the presence of anti-WNV antibodies in intravenous immunoglobulin (IVIG) from Israeli donors (IVIG-IL) assisted the recovery of patients with severe WNV infection.</p> <p>Methods</p> <p>To enhance the therapeutic efficacy of IVIG-IL against WNV infection, OMRIX Biopharmaceuticals, Israel, have developed a strategy for selection of plasma units from a 10% fraction of Israeli blood donors with anti-WNV antibodies. Positive units were processed into pharmaceutical grade WNV IVIG (WNIG). Following inoculation with WNV, mice received i.p. injections of different doses (0.01–8 mg/mouse) of IVIG-IL or WNIG, according to the specific experimental protocol.</p> <p>Results</p> <p>WNIG was about 10 times more potent (per gr of IgG) than was regular IVIG-IL when tested by ELISA and neutralization assays. In a mouse lethal WNV infection model, prophylactic treatment with WNIG was at least 5–10-fold more potent as compared to treatment with IVIG-IL. Treatment with WNIG during active encephalitis, three or four days following WNV infection, had a significant protective effect. WNIG was also very effective in protecting immunosuppressed mice. Indeed, treatment of dexamethasone-immunosuppressed mice with 0.2 or 1.0 mg WNIG 4 h after virus infection, led to 100% survival.</p> <p>Conclusion</p> <p>IVIG produced from selected plasma donated in WNV endemic regions can be used to produce WNV IVIG with superior activity for therapeutic and prophylactic measures.</p>http://www.biomedcentral.com/1471-2334/9/18 |
| spellingShingle | Gottreich Ahuva Laub Orgad Nur Israel Khinich Yevgeny Samina Itzchak Gershoni-Yahalom Orly Ben-Nathan David Simanov Michael Porgador Angel Rager-Zisman Bracha Orr Nadav Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection BMC Infectious Diseases |
| title | Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection |
| title_full | Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection |
| title_fullStr | Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection |
| title_full_unstemmed | Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection |
| title_short | Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection |
| title_sort | using high titer west nile intravenous immunoglobulin from selected israeli donors for treatment of west nile virus infection |
| url | http://www.biomedcentral.com/1471-2334/9/18 |
| work_keys_str_mv | AT gottreichahuva usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT lauborgad usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT nurisrael usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT khinichyevgeny usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT saminaitzchak usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT gershoniyahalomorly usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT bennathandavid usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT simanovmichael usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT porgadorangel usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT ragerzismanbracha usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection AT orrnadav usinghightiterwestnileintravenousimmunoglobulinfromselectedisraelidonorsfortreatmentofwestnilevirusinfection |